Bert Labs strengthens its Pharma capabilities with senior level appointments

 Bert Labs, a global new age deep tech company, solving the world’s challenges by ensuring efficient use of available resources through its patented AI-IoT powered Bert Platform Solution, today announced that it has appointed, Dr Dinabandhu Naskar as Director & Bert Evangelist, Pharma Research, Dr Rudresha Prasad as Director & Bert Evangelist, Pharma Manufacturing, and Shailendra Borole as Bert Evangelist, Pharma Engineering. This appointment comes as Bert Labs continues explore applications of Bert Platform Solution in several industry verticals and in-line with its domain led growth strategy.

The applications of AI-IOT in the pharma industry is largely a virgin territory, with highly complex problems, and the revenue opportunity is untapped. For Bert Labs, the focus for the next four years, towards its $ 1 billion revenue target, is to help Pharma Fortune 500 companies make the drug discovery and development process, pharma manufacturing process, pharma engineering process very efficient, in terms of cost and time. Bert research and innovation will help these companies to achieve their ESG, Sustainability, Energy Efficiency Improvement, Zero Carbon, Carbon Neutrality and Capital Efficiency goals, worldwide.

Welcoming the newly formed Bert Pharma team, Rohit Kochar, Founder, Executive Chairman & CEO, Bert Labs said, “At Bert Labs, we are thrilled to build Bert Pharma team to address the core issues for our clients and build proficiency. Bert journey is of Research & Innovation, uncompromisable integrity & value systems, and entrepreneurial leadership. We are here to build Bert Labs into one of the leading global technology conglomerates and these decisive appointments showcase our commitment, capability, and willingness to solve complex problems for our clients and enabling their innovation for higher quality drugs, and be more capital efficient, profitable, and smarter with their customers.”

“I am fortunate to take on this new responsibility and looking forward to work with our clients in drug discovery and development process. With a speciality team in place, we will be able to provide the best of service with custom made solutions to our pharma clients. I am here to make a difference and to be at the forefront of innovation, as we collaborate with Pharma, Biotech and Research institutes across the globe to deliver recurring value to each one of our customers”, said Dr Dinabandhu Naskar.

Bert Labs believes in onboarding individuals who have the common thread of being bound through the value systems and inspiring, skilful, talented, and knowledgeable in our Bert journey. We look for the talent who have a sense of ownership to deliver on their responsibility, be it on innovation, solutioning, signing a sales deal or an investment closure.

Dinabandhu, Rudhresha, and Shailendra are highly recognized in their field, and we look forward to working with them in meeting our corporate strategic goals.

Dr Dinabandhu Naskar, who is Director & Bert Evangelist – Pharma Research, was VP, Syngene (a Bicocon Company), in his 20+ years of experience as Lead Investigator & Senior Scientist in Drug Discovery & Development. He has PhD from Indian Institute of Chemical Technology, Hyderabad and Post-Doctoral Fellowship from University of Gottingen, in Germany.

Dr Rudresha Prasad is Director & Bert Evangelist – Pharma Manufacturing. Rudresha was VP, GSK, responsible for technical process of all manufacturing plants in India. He has PhD from IISc and 2 Post-Doctoral Fellowships from University of Strathclyde and Oxford University.  

Shailendra Borole is Bert Pharma HVAC/Utility Expert. Shailendra was responsible for 21 years for Projects and Engineering at Cipla.

This team is a part of the Bert Labs endeavour to build its domain expertise in the focussed verticals to solve real life problems for clients, globally with unmatched Bert Platform Solution, which speeds up the drug R&D process, enabling companies to differentiate their products by delivering healthcare solutions to hospitals and patients faster than otherwise possible. It reduces R&D costs while boosting clinical trial success rates, which translates to increases profit margins for pharma businesses. Integrating IoT and AI into patient management solutions helps to improve medication adherence and treatment outcomes, resulting in, in-market success.